The representation of Black and Asian adults is on the rise in atopic dermatitis clinical trials, according to a study. As ...

VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) verbally informed ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

For mild cases of traction alopecia, minoxidil may only need to be used for 12 months to fully restore the hairline. However, ...

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company that it placed a clinical hold on the ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

BDO attended the IncluDE Site Solutions Summit, a gathering of the best focused on enhancing diversity, equity, and inclusion ...

From high blood pressure to heart disease and clinical trials, this conversation pulls back the curtain on issues that impact ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

A new study in Scientific Reports reveals that skin shame is a key psychological burden for people with atopic dermatitis and ...

Low-grade systemic inflammation is an independent risk factor for psoriasis, especially moderate to severe disease, results ...

Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom ...